The Multi-Arm GlioblastoMa Australasia (MAGMA) Trial is a platform trial that will assess a number of options in standard of care for the management of glioblastoma. Initial questions of interest are: QUESTION 1 whether or not to give a cycle of temozolomide prior to chemoradiotherapy and QUESTION 2: whether to give 6 cycles of temozolomide after chemoradiotherapy, or continue monthly treatment until disease progression

Abstract

This study aims to evaluate the use of temozolomide in different regimes for Glioblastoma. The trial is testing two changes to the usual schedule of treatment.

Who is it for?

You may eligible for this study if you are a male or female aged 18 years or older, with newly diagnosed, histologically confirmed grade IV malignant glioblastoma.

For the initial questions of interest, participants will be randomly allocated (50/50) chance to one of two treatment groups, to either

QUESTION 1: Intervention Arm 1: After surgery, start temozolomide as soon as possible prior to chemoradiotherapy Control Arm 2: After surgery, start temozolomide at the same time as radiotherapy

QUESTION 2: Intervention Arm 1: After chemoradiotherapy, take adjuvant temozolomide until disease progression Control Arm 2: After chemoradiotherapy, take adjuvant temozolomide for 6 cycles

For participants that choose not to be randomly allocated treatment will be at patient/doctor discretion.

All participants will be asked to have blood tests and scans as you would for usual treatment, the extra things requested are to fill out questionnaires and donate extra blood tests.

It is hoped this research will help identify if starting temozolomide earlier than usual and/or continuing treatment with temozolomide for longer than usual will improve the outcomes of people with glioblastoma and assist development of future treatments.